206 related articles for article (PubMed ID: 25989829)
1. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Ciaffi L; Cavassini M; Genne D; Delhumeau C; Spycher Elbes R; Hill A; Wandeler G; Fehr J; Stoeckle M; Schmid P; Hirschel B; Montecucco F; Calmy A;
Eur J Clin Invest; 2015 Jul; 45(7):720-30. PubMed ID: 25989829
[TBL] [Abstract][Full Text] [Related]
2. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
[TBL] [Abstract][Full Text] [Related]
3. A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
5. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
[TBL] [Abstract][Full Text] [Related]
7. Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Mankhatitham W; Luaengniyomkul A; Manosuthi W
J Med Assoc Thai; 2012 Feb; 95(2):163-9. PubMed ID: 22435244
[TBL] [Abstract][Full Text] [Related]
8. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
Schneider L; Ktorza N; Fourati S; Assoumou L; Courbon E; Caby F; Blanc C; Tindel M; Agher R; Marcelin AG; Calvez V; Peytavin G; Katlama C
HIV Clin Trials; 2012; 13(5):284-8. PubMed ID: 23134629
[TBL] [Abstract][Full Text] [Related]
9. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
Negredo E; Moltó J; Puig J; Cinquegrana D; Bonjoch A; Pérez-Alvarez N; López-Blázquez R; Blanco A; Clotet B; Rey-Joly C
AIDS; 2006 Nov; 20(17):2159-64. PubMed ID: 17086055
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabie A; Cheret A; Lahoulou R; Raffi F; Pugliese P;
Infect Dis (Lond); 2016; 48(5):392-8. PubMed ID: 26757613
[TBL] [Abstract][Full Text] [Related]
11. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
[TBL] [Abstract][Full Text] [Related]
12. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
Córdova E; Loiza E; Porteiro N; Mingrone H
Enferm Infecc Microbiol Clin; 2011; 29(6):428-31. PubMed ID: 21592625
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
[TBL] [Abstract][Full Text] [Related]
14. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
15. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.
Allavena C; Katlama C; Cotte L; Roger PM; Delobel P; Cheret A; Duvivier C; Poizot-Martin I; Hoen B; Cabié A; Cheret A; Lahoulou R; Raffi F; Pugliese P
J Int AIDS Soc; 2014; 17(4 Suppl 3):19780. PubMed ID: 25397524
[TBL] [Abstract][Full Text] [Related]
17. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G; Duvivier C; Rieger A; Durant J; Rey D; Schmidt W; Hill A; van Delft Y; Marks S;
J Antimicrob Chemother; 2012 Mar; 67(3):685-90. PubMed ID: 22210755
[TBL] [Abstract][Full Text] [Related]
18. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
19. Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H; Stürner KH; Höhn C; Braun P
HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
